Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491836 | ||
| 003 | CHVBK | ||
| 005 | 20210128100512.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150401xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0707-1 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0707-1 | ||
| 245 | 0 | 0 | |a Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab |h [Elektronische Daten] |c [Alexandre da Costa, Felipe D'Almeida Costa, Adriana Ribeiro, Andréia Guimarães, Ludmila Chinen, Clóvis Lopes, Vladmir de Lima] |
| 520 | 3 | |a Background: Platinum-based chemotherapy associated with cetuximab is the first-line treatment for inoperable recurrence or metastatic head and neck squamous cell carcinoma (HNSCC). There is no established biomarker for cetuximab efficacy in HNSCC. The PI3K pathway is one of the most frequently altered pathways in HNSCC. Loss of phosphatase and tensin homolog (PTEN) expression occurs in up to 30% of cases. Methods: This was a retrospective analysis of data from 61 patients with inoperable recurrence or metastatic HNSCC treated with cetuximab. PTEN, epidermal growth factor receptor and p16 expression were analyzed by immunohistochemistry and tested for association with clinical outcomes. Results: Median overall survival was 11.4months and progression-free survival was 6.9months. Low PTEN expression was present in 26.2% of patients and identified patients with worse prognosis. p16 was positive in only 8.5% of tumors. Conclusions: Low PTEN expression in patients treated with cetuximab plus chemotherapy emerged as a prognostic biomarker and should be evaluated for its predictive role for cetuximab efficacy. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a PTEN |2 nationallicence | |
| 690 | 7 | |a p16 |2 nationallicence | |
| 690 | 7 | |a Cetuximab |2 nationallicence | |
| 690 | 7 | |a Head and neck cancer |2 nationallicence | |
| 690 | 7 | |a Biomarker |2 nationallicence | |
| 690 | 7 | |a Prognosis |2 nationallicence | |
| 700 | 1 | |a da Costa |D Alexandre |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a D'Almeida Costa |D Felipe |u Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a Ribeiro |D Adriana |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a Guimarães |D Andréia |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a Chinen |D Ludmila |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a Lopes |D Clóvis |u Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a de Lima |D Vladmir |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 282-289 |x 1341-9625 |q 20:2<282 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0707-1 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0707-1 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a da Costa |D Alexandre |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a D'Almeida Costa |D Felipe |u Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ribeiro |D Adriana |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Guimarães |D Andréia |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chinen |D Ludmila |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lopes |D Clóvis |u Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a de Lima |D Vladmir |u Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 282-289 |x 1341-9625 |q 20:2<282 |1 2015 |2 20 |o 10147 | ||